Norfloxacin Dosing Recommendations
Norfloxacin is dosed at 400 mg twice daily for most urinary tract infections, with treatment duration varying from 3 days for uncomplicated cystitis to 28 days for chronic prostatitis, and requires dose adjustment to 400 mg once daily in patients with creatinine clearance below 30 mL/min.
Standard Dosing Regimens
Uncomplicated Urinary Tract Infections (Cystitis)
- Dose: 400 mg orally twice daily
- Duration: 3 days for uncomplicated cystitis 1
- Evidence: Three-day therapy is significantly more effective than single-dose therapy (88% vs 78% cure rates at 4-6 weeks), particularly for non-E. coli pathogens like Staphylococcus saprophyticus 1. While 800 mg once daily has been studied and shown equivalent efficacy to 400 mg twice daily 2, the twice-daily regimen remains standard.
Complicated Urinary Tract Infections
- Dose: 400 mg orally twice daily
- Duration: 7-10 days minimum, up to 30 days for severe cases
- Evidence: In men with complicated UTIs (including benign prostatic hypertrophy, urethral stricture, indwelling catheters), norfloxacin 400 mg twice daily achieved 75% cure rates with treatment durations of 7-30 days 3
Acute Prostatitis
- Dose: 400 mg orally twice daily
- Duration: 28 days (4 weeks) minimum
- Note: While the FDA label 4 references ofloxacin dosing for prostatitis at 300 mg twice daily for 6 weeks, norfloxacin for prostatitis typically requires at least 4 weeks of therapy given the difficulty of achieving adequate prostatic tissue penetration.
Traveler's Diarrhea
- Norfloxacin is NOT recommended as first-line therapy for traveler's diarrhea
- Current guidelines 5 recommend azithromycin, levofloxacin, or ciprofloxacin instead
- If fluoroquinolones are used: ciprofloxacin 500-750 mg or levofloxacin 500 mg are preferred over norfloxacin
- Rationale: Norfloxacin has poor systemic absorption and is primarily concentrated in urine, making it suboptimal for gastrointestinal infections
Typhoid Fever
- Norfloxacin is NOT appropriate for typhoid fever treatment
- Systemic fluoroquinolones (ciprofloxacin, levofloxacin, ofloxacin) are required for invasive enteric infections
- Norfloxacin's limited systemic bioavailability makes it unsuitable for bloodstream and tissue infections
Renal Dose Adjustment
Severe Renal Impairment
- Creatinine clearance < 30 mL/min: 400 mg once daily (half the usual dose)
- Creatinine clearance 30-50 mL/min: Consider 400 mg once daily, though some sources suggest standard dosing may be acceptable
- Dialysis patients: 400 mg once daily
Critical caveat: Norfloxacin should be avoided entirely in patients with significant renal impairment when other options exist, as the risk of adverse effects (particularly neurologic complications) increases substantially 6.
Important Clinical Considerations
Efficacy Profile
- Highly effective against E. coli (97% susceptibility in historical studies) 3
- Less effective against Pseudomonas aeruginosa and enterococci, with resistance development possible during therapy 3
- Maintains good activity against S. saprophyticus and most common uropathogens 7
Safety Profile
- Overall adverse event rate: 7-14% 8, 2
- Most common: nausea, headache, dizziness (< 3% each) 7
- Drug-related discontinuation rate: 0.8-2.2% 8
- Serious risks with prolonged use: pulmonary reactions and polyneuropathy 6
Current Guideline Context
Norfloxacin is notably absent from current European and American UTI guidelines 9, 5. The 2024 EAU guidelines recommend ciprofloxacin or levofloxacin for pyelonephritis but do not mention norfloxacin 9. This reflects the availability of fluoroquinolones with better pharmacokinetic profiles and broader clinical evidence.
Drug Interactions
Separate norfloxacin administration by 2 hours from:
- Antacids containing calcium, magnesium, or aluminum
- Iron supplements
- Multivitamins with zinc
- Sucralfate
When NOT to Use Norfloxacin
- Systemic infections (poor tissue penetration)
- Pyelonephritis (inadequate renal tissue levels compared to ciprofloxacin/levofloxacin)
- Pregnancy (especially third trimester)
- Any degree of renal impairment if alternatives available
- Gastrointestinal infections requiring systemic therapy